Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Melanoma 258 Carcinoma, Non-Small-Cell Lung 226 Carcinoma, Renal Cell 143 Neoplasm Metastasis 97 Neoplasms 93 Carcinoma, Hepatocellular 85 Squamous Cell Carcinoma of Head and Neck 84 Colorectal Neoplasms 81 Lung Neoplasms 73 Stomach Neoplasms 56 Pancreatic Neoplasms 56 Carcinoma, Transitional Cell 49 Hodgkin Disease 47 Urinary Bladder Neoplasms 42 Breast Neoplasms 40 Ovarian Neoplasms 37 Head and Neck Neoplasms 37 Triple Negative Breast Neoplasms 34 Small Cell Lung Carcinoma 33 Sarcoma 32 Prostatic Neoplasms 32 Glioblastoma 32 Brain Neoplasms 32 Recurrence 27 Kidney Neoplasms 27 Multiple Myeloma 25 Uveal Melanoma 23 Esophageal Neoplasms 23 Uterine Cervical Neoplasms 22 Skin Neoplasms 22

Interventions

pembrolizumab 3 Paclitaxel 2 relatlimab 1 nintedanib 1 lifileucel 1 dabrafenib 1 Vitamin D 1 Temozolomide 1 Surveys and Questionnaires 1 Opdualag 1 Nivolumab 1 Ipilimumab 1 Eye Movement Desensitization Reprocessing 1 Electrochemotherapy 1 Dacarbazine 1 Cholecalciferol 1 Carboplatin 1 Albumin-Bound Paclitaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Melanoma, Cutaneous Malignant × Nivolumab × Clear all

NCT06743126 2026-05-29

SUPRAME

Immatics US, Inc.

Phase 3 Recruiting

Melanoma, Cutaneous Malignant

Data powered by HemOnc (CC BY 4.0) Colophon ⚡